Back to search

University of British Columbia

Localized delivery of resiquimod for enhanced immunotherapy of peritoneal metastasis

Abstract

dc:description

Metastases in the peritoneum arise primarily from colorectal, ovarian, and gastric cancers, with colorectal and ovarian origins being the most prevalent. Peritoneal metastasis is marked by a high recurrence rate and mortality following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC), mainly due to the incomplete eradication of cancer cells. Immunotherapy has gained traction rapidly in the past decades as a promising cancer treatment strategy, reactivating the immune system within the tumor microenvironment to attack cancer cells, which can lead to complete eradication when combined with chemotherapy. However, the efficacy of immunomodulatory agents is often hindered by solubility challenges. To address this issue, this dissertation focuses on developing novel immune boosting liposomal systems to enhance the delivery and efficacy of immunomodulatory agents for treating peritoneal metastasis. Oxaliplatin (OXA), an immunogenic cell death inducer used in HIPEC, was selected to promote the release of tumor antigens. Our formulations demonstrate that they can augment the existing therapy by leveraging the immune response against cancer. The first part of this dissertation focuses on developing a liposomal nanocarrier with a cationic lipid, allowing for localization of a toll-like receptor agonist, resiquimod (R848), within the peritoneal cavity. I evaluated the pharmacokinetic profile, immune cell uptake, tumor growth inhibition, and immune-modulating ability of this formulation. The second part of this thesis investigates utilizing a multivalent cationic lipopeptide to further improve the peritoneal retention of R848. A novel multivalent cationic lipopeptide-modified liposomal formulation was developed and characterized. I also performed a comparative analysis with the initial formulation regarding pharmacokinetics and in vivo immune activation. The third part of this dissertation explores anti-tumor efficacy, tumor immune infiltration, and specific long-term immunity against the cancer. In addition to assessing their efficacies in a murine tumor model, I studied the immune microenvironment reprogramming and the roles of various immune cell populations in cancer treatment using an immune depletion assay. This thesis demonstrates that cationic liposomal formulations, combined with current chemotherapy, hold promise for improving existing therapies for peritoneal metastasis. These advancements could significantly enhance treatment outcomes by addressing the challenges of R848 and optimizing the immune response against cancer.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy - PhD
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Pharmaceutical Sciences
Grantor dc:publisher
University of British Columbia
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Chao, Po-Han
Contributors dc:contributor
  • Li, Shyh-Dar

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/89352

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Chao, Po-Han. Localized delivery of resiquimod for enhanced immunotherapy of peritoneal metastasis. doctoral thesis, University of British Columbia, 2024. http://hdl.handle.net/2429/89352